Tecemotide

BIOLOGICAL4 trials

Sponsors

ECOG-ACRIN Cancer Research Group, Merck KGaA, Darmstadt, Germany, EMD Serono

Conditions

Carcinoma, Non-Small-Cell LungLung CancerMultiple MyelomaNon-Small Cell Lung Cancer

Phase 2

BLP25 Liposome Vaccine and Bevacizumab After Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery

CompletedNCT00828009

ECOG-ACRIN Cancer Research GroupLung Cancer

Start: 2011-01-17End: 2019-05-22Updated: 2023-07-07

Phase 3

Cancer Vaccine Study for Stage III, Unresectable, Non-small Cell Lung Cancer (NSCLC) in the Asian Population

TerminatedNCT01015443

Merck KGaA, Darmstadt, GermanyNon-Small Cell Lung Cancer

Start: 2009-12-31End: 2015-06-30Updated: 2016-10-26

Tecemotide Following Concurrent Chemo-radiotherapy for Non-small Cell Lung Cancer

TerminatedNCT02049151

EMD SeronoCarcinoma, Non-Small-Cell Lung

Start: 2014-03-31End: 2015-07-31Updated: 2017-08-23

Unknown Phase

Common Safety Follow-up Trial of Tecemotide (L-BLP25)

TerminatedNCT01423760

Merck KGaA, Darmstadt, GermanyMultiple Myeloma, Non-Small Cell Lung Cancer

Start: 2012-01-31End: 2015-08-31Updated: 2016-10-06

Related Papers

START2: Tecemotide in unresectable stage III NSCLC after first-line concurrent chemoradiotherapy.

Journal of Clinical Oncology2014-05-205 citations

Multiple therapeutic peptide vaccines consisting of combined novel cancer testis antigens and anti-angiogenic peptides for patients with non-small cell lung cancer.

2013-04-1162 citations

INSPIRE: A phase III study of the BLP25 liposome vaccine (L-BLP25) in Asian patients with unresectable stage III non-small cell lung cancer.

2011-10-0760 citations